Jasper Therapeutics’ (JSPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $40.00 target price on the stock.

JSPR has been the subject of several other research reports. Royal Bank of Canada decreased their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th. JMP Securities reiterated a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a report on Monday, January 6th. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price objective for the company. Finally, UBS Group initiated coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $38.00 price objective for the company. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $62.50.

Jasper Therapeutics Trading Down 0.2 %

NASDAQ JSPR opened at $5.38 on Tuesday. Jasper Therapeutics has a 52 week low of $4.55 and a 52 week high of $31.01. The stock has a market cap of $80.82 million, a price-to-earnings ratio of -1.14 and a beta of 2.23. The company has a 50-day moving average price of $7.04 and a two-hundred day moving average price of $16.01.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35). As a group, equities research analysts expect that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

Institutional Trading of Jasper Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets lifted its stake in Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after purchasing an additional 1,698 shares during the last quarter. MetLife Investment Management LLC lifted its stake in Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after purchasing an additional 3,873 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after purchasing an additional 3,828 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in Jasper Therapeutics during the fourth quarter valued at approximately $223,000. Finally, Tema Etfs LLC acquired a new stake in Jasper Therapeutics during the fourth quarter valued at approximately $266,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.